I. Original Articles

1.

Sakai D, Matsumiya W (corresponding author), Kusuhara S, Nakamura M. Factors
associated with the development of ocular candidiasis and ocular prognosis withechinocandin therapy for candidemia. J Ophthalmic Inflamm Infect. 2021 Jun 14;11(1):17.

2.

Kim KW, Kusuhara S, Katsuyama-Yoshikawa A, Nobuyoshi S, Kitamura M, Mori S,Sotani N, Ueda K, Matsumiya W, Miki A, Kurimoto T, Imai H, Nakamura M. Changes in
Gene Expression Profiling and Phenotype in Aged Multidrug Resistance Protein 4Deficient Mouse Retinas. Antioxidants (Basel). 2021 Mar 15;10(3):455. doi:
10.3390/antiox10030455.

3.

Nishisho R, Kusuhara S, Sotani N, Kim KW, Katsuyama-Yoshikawa A, Matsumiya W,Akashi K, Morinobu A, Nakamura M. Changes in choroidal imaging parameters following
adalimumab therapy for refractory noninfectious uveitis. Graefes Arch Clin Exp
Ophthalmol. 2021 Jan 7. doi: 10.1007/s00417-020-05032-9. Online ahead of print.

4.

Hayashida M, Miki A, Nakai S, Matsumiya W, Imai H, Kusuhara S, Nakamura M.
Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy inpatients with central serous chorioretinopathy with good baseline visual acuity. PLoS One.
2020 Oct 12;15(10):e0240557. doi: 10.1371/journal.pone.0240557. eCollection 2020.

5.

Kurimoto T, Ueda K, Mori S, Kamada S, Sakamoto M, Yamada-Nakanishi Y, Matsumiya
W, Nakamura M. A Single-Arm, Prospective, Exploratory Study to Preliminarily Test
Effectiveness and Safety of Skin Electrical Stimulation for Leber Hereditary Optic
Neuropathy. J Clin Med. 2020 May 6;9(5):1359. doi: 10.3390/jcm9051359.

6.

Katsuyama A, Kusuhara S, Asahara SI, Nakai SI, Mori S, Matsumiya W, Miki A,Kurimoto T, Imai H, Kido Y, Ogawa W, Nakamura M. En face slab optical coherence
tomography imaging successfully monitors progressive degenerative changes in theinnermost layer of the diabetic retina. BMJ Open Diabetes Res Care. 2020
Mar;8(1):e001120.

7.

Tetsumoto A, Imai H, Hayashida M, Otsuka K, Matsumiya W, Miki A, Nakamura M. The
comparison of the surgical outcome of 27-gauge pars plana vitrectomy for primaryrhegmatogenous retinal detachment between air and SF6 gas tamponade. Eye (Lond). 2020
Feb;34(2):299-306.

8.

Katsuyama A, Kusuhara S, Awano H, Nagase H, Matsumiya W, Nakamura M. A case ofprobable Vogt-Koyanagi-Harada disease in a 3-year-old girl. BMC Ophthalmol. 2019 Aug
13;19(1):179. doi: 10.1186/s12886-019-1192-0.

9.

Tetsumoto A, Imai H, Otsuka K, Matsumiya W, Miki A, Nakamura M.Clinical factors
contributing to postoperative aqueous flare intensity after 27-gauge pars plana vitrectomy
for the primary rhegmatogenous retinal detachment. Jpn J Ophthalmol. 2019 May 18. doi:10.1007/s10384-019-00672-9.

10. Katsuyama A, Kusuhara S, Nishisho R, Matsumiya W, Azumi A, Nakamura M. Longterm efficacy and safety of infliximab and cyclosporine combination therapy for refractory
uveoretinitis in Behçet's disease. Clin Ophthalmol. 2019 Mar 20;13:521-527.

11. Nakai S, Matsumiya W (corresponding author), Keiko O, Miki A, Nakamura M, Honda S.
The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy
for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2019 Jan;63(1):100-108.

12. Nagano C, Nozu K, Yamamura T, Minamikawa S, Fujimura J, Sakakibara N, Nakanishi K,Horinouchi T, Iwafuchi Y, Kusuhara S, Matsumiya W, Yoshikawa N, Iijima K. TGFBIassociated corneal dystrophy and nephropathy: a novel syndrome? CEN Case Rep. 2018
Aug 7. doi: 10.1007/s13730-018-0356-8.

13. Kusuhara S, Katsuyama A, Matsumiya W, Nakamura M. Efficacy and safety of ripasudil,
a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp
Ophthalmol. 2018 Apr;256(4):809-814. doi: 10.1007/s00417-018-3933-9. Epub 2018 Feb
21.

14. Sugiyama A, Sakurada Y, Honda S, Miki A, Matsumiya W, Yoneyama S, Kikushima W,Iijima H. Retreatment of Exudative Age-Related Macular Degeneration after Loading 3Monthly Intravitreal Ranibizumab. Ophthalmologica. 2018;239(1):52-59.

15. Yamashiro K, Mori K, Honda S, Kano M, Yanagi Y, Obana A, Sakurada Y, Sato T, NagaiY, Hikichi T, Kataoka Y, Hara C, Koyama Y, Koizumi H, Yoshikawa M, Miyake M,Nakata I, Tsuchihashi T, Horie-Inoue K, Matsumiya W, Ogasawara M, Obata R,Yoneyama S, Matsumoto H, Ohnaka M, Kitamei H, Sayanagi K, Ooto S, Tamura H, Oishi
A, Kabasawa S, Ueyama K, Miki A, Kondo N, Bessho H, Saito M, Takahashi H, Tan X,Azuma K, Kikushima W, Mukai R, Ohira A, Gomi F, Miyata K, Takahashi K, Kishi S,Iijima H, Sekiryu T, Iida T, Awata T, Inoue S, Yamada R, Matsuda F, Tsujikawa A, NegiA, Yoneya S, Iwata T, Yoshimura N. A prospective multicenter study on genome wideassociations to ranibizumab treatment outcome for age-related macular degeneration. SciRep. 2017 Aug 23;7(1):9196.

16. Nakai S, Honda S, Matsumiya W, Miki A, Nakamura M. ARMS2 variants may predictthe 3-year outcome of photodynamic therapy for wet age-related macular degeneration.
Mol Vis. 2017 Jul 26;23:514-519.

17. Nakai S, Honda S, Miki A, Matsumiya W, Nakamura M. Comparison of the 12-Month
Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal
Choroidal Vasculopathy. Ophthalmologica. 2017;237(3):123-127.

18. Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M.
One-year outcome of combination therapy with intravitreal aflibercept and verteporfin
photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp

Ophthalmol. 2017;255(3):541-548.

19. Enomoto H, Miki A, Matsumiya W, Honda S. Ophthalmologica. 2015;234(3):135-8.
Evaluation of Oxygen Supplementation Status as a Risk Factor Associated with theDevelopment of Severe Retinopathy of Prematurity.

20. Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M.
Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab
between Typical Neovascular Age-Related Macular Degeneration and Polypoidal
Choroidal Vasculopathy over 24 Months of Follow-Up. Ophthalmologica. 2015;234(1):339.

21. Ueda K, Matsumiya W (corresponding author), Otsuka K, Maeda Y, Nagai T, Nakamura
M. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment
in dry eye. BMC Ophthalmol. 2015 Jun 6;15:58.

22. Yanagisawa S, Sakurada Y, Miki A, Matsumiya W, Imoto I, Honda S. The association ofelastin gene variants with two angiographic subtypes of polypoidal choroidal vasculopathy.
PLoS One. 2015 Mar 16;10(3):e0120643.

23. Hirose M, Matsumiya W, Honda S, Nakamura M. Efficacy and visual prognostic factorsof intravitreal bevacizumab as needed for macular edema secondary to central retinal veinocclusion. Clin Ophthalmol. 2014 Nov 19;8:2301-5.

24. Kusuhara S, Matsumiya W, Imai H, Honda S, Tsukahara Y, Negi A. Evaluating
dissociated optic nerve fiber layer appearance using en face layer imaging produced by
optical coherence tomography. Ophthalmologica. 2014;232(3):170-8.

25. Tagami M, Matsumiya W, Imai H, Kusuhara S, Honda S, Azumi A. Autologous
antibodies to outer retina in acute zonal occult outer retinopathy. Jpn J Ophthalmol. 2014
Nov;58(6):462-72.

26. Honda S, Miki A, Yanagisawa S, Matsumiya W, Nagai T, Tsukahara Y. Comparison of
the outcomes of photodynamic therapy between two angiographic subtypes of polypoidal
choroidal vasculopathy. Ophthalmologica. 2014;232(2):92-6.

27. Matsumiya W, Honda S, Yanagisawa S, Miki A, Nagai T, Tsukahara Y. Evaluation ofclinical and genetic indicators for the early response to intravitreal ranibizumab in
exudative age-related macular degeneration. Pharmacogenomics. 2014 Apr;15(6):833-43.

28. Matsumiya W, Honda S, Kusuhara S, Tsukahara Y, Negi A. Effectiveness of intravitreal
ranibizumab in exudative age-related macular degeneration (AMD): comparison between
typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.
BMC Ophthalmol. 2013 Apr 4;13:10.

29. Matsumiya W, Kusuhara S, Shimoyama T, Honda S, Tsukahara Y, Negi A. Predictive
value of preoperative optical coherence tomography for visual outcome following macularhole surgery: effects of imaging alignment. Jpn J Ophthalmol. 2013 May;57(3):308-15.

30. Matsumiya W, Kusuhara S, Hayashibe K, Maruyama K, Kusuhara H, Tagami M, Schuetz
JD, Negi A. Forskolin modifies retinal vascular development in Mrp4-knockout mice.
Invest Ophthalmol Vis Sci. 2012 Dec 7;53(13):8029-35.

31. Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, Honda S,Negi A. Difference between age-related macular degeneration and polypoidal choroidal
vasculopathy in the hereditary contribution of the A69S variant of the age-related
maculopathy susceptibility 2 gene (ARMS2). Mol Vis. 2011;17:3574-82.

32. Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, Honda S,Negi A. A common complement C3 variant is associated with protection against wet agerelated macular degeneration in a Japanese population. PLoS One. 2011;6(12):e28847.

33. Kishimoto H, Kusuhara S, Matsumiya W, Nagai T, Negi A. Retinal surface imaging
provided by Cirrus high-definition optical coherence tomography prominently visualizes adissociated optic nerve fiber layer appearance after macular hole surgery. Int Ophthalmol.
2011 Oct;31(5):385-92.

34. Matsumiya W, Honda S, Bessho H, Kusuhara S, Tsukahara Y, Negi A. Early responses tointravitreal ranibizumab in typical neovascular age-related macular degeneration andpolypoidal choroidal vasculopathy. J Ophthalmol. 2011;2011:742020.

35. Matsuo M, Honda S, Matsumiya W, Kusuhara S, Tsukahara Y, Negi A. Comparison
between anti-vascular endothelial growth factor therapy and photodynamic therapy formyopic choroidal neovascularization. Eur J Ophthalmol. 2012 Mar-Apr;22(2):210-5.

II. Case Reports

1. Matsumiya W, Karaca I, Ghoraba H, Akhavanrezayat A, Mobasserian A, Hassan M,Regenold J, Yasar C, Liedtke M, Kitazawa K, Nguyen QD. Structural changes of corneal
epithelium in belantamab-associated superficial keratopathy using anterior segment opticalcoherence tomography. Am J Ophthalmol Case Rep. 2021 Jun 9;23:101133.

2. Kim KW, Kusuhara S, Tachihara M, Mimura C, Matsumiya W, Nakamura M. A case ofpanuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lungcancer. Am J Ophthalmol Case Rep. 2021 Mar 12;22:101072. doi:10.1016/j.ajoc.2021.101072.

3. Pham BH, Hien DL, Matsumiya W, Tuong Ngoc TT, Doan HL, Akhavanrezayat A, Yaşar Ç,Nguyen HV, Halim MS, Nguyen QD. Anti-interleukin-6 receptor therapy with tocilizumab
for refractory pseudophakic cystoid macular edema. Am J Ophthalmol Case Rep. 2020 Aug
20;20:100881. doi: 10.1016/j.ajoc.2020.100881.

4. Sakai D, Matsumiya W(corresponding author), Kusuhara S, Nakamura M. The choroidal
structure changes in a case with hypertensive choroidopathy. Am J Ophthalmol Case Rep.
2020;18:100710. Published 2020 Apr 13. doi:10.1016/j.ajoc.2020.1007105. Jain A, Chea S, Matsumiya W, Halim MS, Yaşar Ç, Kuang G, Sepah YJ, Khanani AM, DoDV, Nguyen QD. Severe vision loss secondary to retinal arteriolar occlusions after multiple
intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020 Apr
2;18:100687. doi: 10.1016/j.ajoc.2020.100687.

6. Matsumiya W, Kusuhara S, Yamada Y, Azumi A, Negi A. Sweet's syndrome with panuveitis
resembling Behçet's disease. Jpn J Ophthalmol. 2012 May;56(3):268-72.

7. Matsumiya W, Honda S, Imai H, Kusuhara S, Tsukahara Y, Negi A. A Case of Bilateral
Macular Holes Showing Onset and Spontaneous Closure over Very Short Intervals. Case RepOphthalmol. 2010 Sep 13;1(2):47-52.
III. Review
1.

Honda S, Matsumiya W, Negi A. Polypoidal choroidal vasculopathy: clinical features andgenetic predisposition. Ophthalmologica. 2014;231(2):59-74.